<DOC>
	<DOCNO>NCT02652650</DOCNO>
	<brief_summary>The purpose study evaluate effect steady-state concentration JNJ-63623872 steady-state pharmacokinetics ethinylestradiol norethindrone healthy female participant .</brief_summary>
	<brief_title>A Study Investigate Effect JNJ-63623872 Steady-state Steady-state Pharmacokinetics Ethinylestradiol Norethindrone</brief_title>
	<detailed_description>This Phase 1 open-label study . The study consist Screening Phase ( less equal ( &lt; = ) 28 day Day 1 ) , Treatment Phase ( Day 1 Day 78 ) Follow Phase ( 10 14 day last study drug intake , adverse event occur , 30 35 day last study drug intake ) . Treatment phase consist three Oral Contraceptive ( OC ) cycle ( cycle consist 21 day ethinylestradiol/norethindrone follow 7 pill-free day ) . The duration treatment phase , include OC-free period Cycles I II , 78 day . Blood sample collect measurement pharmacokinetic ( Pk ) parameter . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Mestranol</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<criteria>Participant must willing able adhere prohibition restriction specify protocol Participants must , heterosexually active partner vasectomize ( confirm sterile ) , practice effective method contraception entry agree continue use two effective method contraception throughout study least 30 day receive last intake oral contraceptive ( OC ) plus JNJ63623872 Day 77 Participants must negative serum pregnancy test screen negative urine pregnancy test Day 1 Cycle I Participants must agree donate egg ( ovum , oocytes ) study least 90 day receive last intake OC plus JNJ63623872 Day 77 Participants must Body Mass Index ( BMI ) ; 18.0 30.0 kilogram per square meter ( kg/m^2 ) ( extremes include ) Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result At screen , participant one laboratory abnormality specify protocol define World Health Organization ( WHO ) Toxicity Grading Scale Participant past history heart arrhythmia ( extrasystole , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( example , hypokalemia , family history long QT Syndrome ) Participants history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticarial Participants history clinically significant drug allergy , limited , sulfonamides penicillin , drug allergy diagnose previous study experimental drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-63623872</keyword>
	<keyword>Ethinylestradiol</keyword>
	<keyword>Norethindrone</keyword>
</DOC>